Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Flecainide has been contraindicated in patients with structural heart disease (SHD) since the 1991 Cardiac Arrhythmia Suppression Trial (CAST) showed increased mortality in post-myocardial infarction patients. This review argues that the CAST findings were overgeneralized, resulting in the underutilization of a valuable antiarrhythmic medication. Emerging observational evidence suggests that flecainide may be safe and effective in specific SHD populations, including those with stable coronary artery disease without active ischemia and preserved ventricular function. Its use also shows promise in various cardiomyopathies such as arrhythmogenic right ventricular cardiomyopathy and premature ventricular complex-induced cardiomyopathy, supporting a nuanced, patient-specific approach that challenges existing flecainide safety dogma and moves beyond outdated misconceptions. Randomized controlled trials are needed to confirm the recent observational findings and redefine the role of flecainide in contemporary cardiology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2025.08.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seeing Is Believing: Intelligence Is Artificial, Responsibility Is Not.
J Am Coll Cardiol
August 2025
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.
Human cardiac organoids for disease modeling and drug discovery.
Trends Mol Med
September 2025
Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Cancer Institute, Cedars-Sinai Medica
Cardiac organoids are 3D self-assembling structures that recapitulate some of the functional, structural, and cellular aspects of the developing heart. Cardiac organoid modeling has overcome many of the limitations of current cardiac modeling systems by providing a human-relevant, multicellular, spatially advanced model that can replicate early key developmental stages of human cardiogenesis. Recent advancements in cardiac organoid modeling have enabled further understanding of cardiogenesis, cardiovascular disease, and drug-induced cardiotoxicity.
View Article and Find Full Text PDFTranscatheter edge-to-edge repair for the management of secondary mitral regurgitation - CRT 2025 Beyond the Guidelines.
Cardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFFlow cytometry of the myocardium: An end-to-end analysis of adult cardiomyocytes isolated from pig and mouse hearts.
J Mol Cell Cardiol
September 2025
Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Selective therapeutic targeting of cardiomyocytes (CMs) and non-myocytes (NMs) within the heart is an active field of research. The success of those novel therapeutic strategies is linked to the ability to accurately assess uptake and gene delivery efficiencies in clinically relevant animal models. Nevertheless, quantification at the single cell level remains a significant challenge.
View Article and Find Full Text PDFBiomarker-Based Surveillance in Heart Transplant Rejection.
Can J Cardiol
September 2025
Division of Cardiology, Hartford HealthCare Heart and Vascular Institute, Hartford, CT, USA. Electronic address:
Post-transplant rejection surveillance remains a cornerstone of heart transplant care. Although endomyocardial biopsy (EMB) has long been the gold standard for detecting rejection, its invasive nature, interobserver variability in histologic interpretation, and limitations in distinguishing between acute cellular rejection (ACR) and antibody-mediated rejection have prompted interest in noninvasive techniques. Traditional biomarkers- such as troponin, C-reactive protein, brain natriuretic peptide, and donor-specific antibodies- offer supplementary assessments of graft function but lack the specificity and sensitivity required to be standalone markers.
View Article and Find Full Text PDF